Latest Breaking News On - Cholesterol efflux - Page 1 : comparemela.com

ZyVersa Therapeutics CEO, Stephen C Glover, to

ZyVersa Therapeutics CEO, Stephen C Glover, to
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

San diego convention centerUnited statesSan diegoStephenc gloverInternational conventionSecurities exchangeZyversa therapeutics incCholesterol efflux mediatorVersa therapeuticsChief executive officerThursday juneCholesterol effluxZyversa therapeuticsSecurities exchange actPrivate securities litigation reform act

ApoA1 Trial Misses Endpoint, But HDL Hypothesis Still Alive?

ApoA1 infusions in acute MI did not significantly reduce the composite endpoint in the AEGIS-II trial. However, an exploratory analysis suggested benefit at higher LDL levels.

United statesBaylor college of medicineChristiem ballantynePamela morrisVijay nambiC michael gibsonSteve nissenUniversity of south carolinaHarvard medical schoolAmerican college of cardiologyAmerican collegeScientific sessionsNew england journalMedical universitySouth carolinaCholesterol efflux

ZyVersa Therapeutics CEO, Stephen C Glover, Featured on Benzinga All Access

ZyVersa Therapeutics CEO, Stephen C Glover, Featured on Benzinga All Access
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Casey mcdonaldDave schemeliaStephenc gloverSecurities exchangeZyversa therapeutics incExchange commissionVersa therapeuticsChief executive officerBenzinga allCholesterol effluxInvestigational new drugZyversa therapeuticsSecurities exchange actPrivate securities litigation reform actAnnual reportQuarterly reports

ZyVersa Therapeutics CEO, Stephen C Glover, Issues Letter

WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical.

Dave schemeliaCasey mcdonaldStephenc gloverZyversa therapeutics incSecurities exchangeExchange commissionVersa therapeuticsChief executive officerCholesterol effluxZyversa therapeuticsSecurities exchange actPrivate securities litigation reform actAnnual reportQuarterly reportsNasdaq zvsaZyversa therapeutics

ZyVersa Therapeutics CEO, Stephen C Glover, Issues Letter to Shareholders Providing Outlook for 2024

ZyVersa Therapeutics CEO, Stephen C Glover, Issues Letter to Shareholders Providing Outlook for 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Casey mcdonaldDave schemeliaStephenc gloverSecurities exchangeExchange commissionZyversa therapeutics incVersa therapeuticsChief executive officerCholesterol effluxZyversa therapeuticsSecurities exchange actPrivate securities litigation reform actAnnual reportQuarterly reports